ADA 2021 Highlights

(可选)
隐私政策.



可在Medfyle App上获得

欢迎浏览2021年ADA集锦

2021年ADA虚拟科学会议提供了一个独特的机会于研究人员和医疗保健专业人员,让他们可分享见解并了解糖尿病治疗方面的重大进展和突破。科学会议于6月25日至29日举行,涵盖了180多场会议和1000场原创研究报告,为与会者提供有关糖尿病领域的全方位教育活动。我们很高兴为您展示这些ADA的精选集锦。

今日之ADA

欢迎来到今日之 ADA–这里收录了美国糖尿病协会第81届科学会议当天节目的精选。每一天,美国糖尿病学会第81届科学会议规划委员会主席达纳达贝拉都会找来一名科学会议主要发言人进行专访,以及她所挑选的线上会议最佳3名演讲者的演示报告,并加上其个人观点和评论。不要担心错过任何内容,您可以在点播会议中重温您错过的任何会议内容。.

ADA领袖访谈

 
 
36
What are your objectives for your term as President of Health Care & Education at the ADA?
196
What will be the long-term professional impact of COVID-19 on clinical care for people with diabetes?
481
How did the pandemic brought an epidemic to light?
716
What are some of the more common mental health issues faced by children with diabetes” or children with insulin-treated diabetes?
 
 
32
How has the overall ADA strategy changed as a result of the pandemic? What does the future hold?
150
The COVID-19 pandemic has disrupted life as we knew it, but it has also offered opportunities – what would you say has changed for the better in diabetes as a result of the pandemic?
216
ADA, together with the EASD, is working on a new consensus report on the management of type 1 diabetes in adults: What’s new?
488
You are only the fifth women to hold the position of ADA President, Science & Medicine - for many years, research and clinical trials involved only men, how important is it for young female diabetologists to be part of the future of research in diabetes?
 
 
32
As Chief Scientific & Medical Officer at the ADA, what are your goals for the association?
183
How important is the partnership with patient organizations, and how does it benefit physicians and people with diabetes?
278
Your research focuses on innovative models of diabetes care. In this regard, what is the ADA doing to improve the lives of people with diabetes?

ADA学院访谈

 
 
18
What percentage of people with type 2 diabetes have cardiorenal complications?
60
What are the key metabolic risks?
120
What role do SGLT2 inhibitors and GLP-1 receptor agonists have to play?
202
How many people who need these agents receive them?
263
What needs to change to fully mitigate cardiorenal risks?
 
 
17
Is there a perception that diabetes care is not the responsibility of cardiologists?
93
What is the link between diabetes and cardiovascular outcomes?
185
What have we learnt from the cardiovascular outcomes trials with SGLT2 inhibitors and GLP-1 receptor agonists?
717
What role could these agents play in the inpatient cardiovascular care setting?
 
 
19
What did you hope to show with the TrialNet study?
71
Have there been any surprises in the results?
203
How can this information shape future treatment options for type 1 diabetes?
浏览更多信息

专家概述

 
 
 
 
 
 
浏览更多信息

摘要

浏览更多信息

发帖人

浏览更多信息
关于ADA 反馈 后测试